Correction: Teprotumumab: A Review in Thyroid Eye Disease

被引：0
|
作者：
Tina Nie
Yvette N. Lamb
机构：
[1] Springer Nature,
来源：
Drugs | 2022年 / 82卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1757 / 1757
相关论文
共 50 条
  • [41] The Effect of Teprotumumab on Ocular Surface Symptoms in Thyroid Eye Disease
    Cale, Mario
    Osias, Ethan
    Singh, Pallavi
    Rootman, Daniel
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
  • [42] Reply Re: "Teprotumumab for the Treatment of Recalcitrant Thyroid Eye Disease"
    Men, Clara J.
    Amarikwa, Linus
    Pham, Brandon
    Sears, Connie
    Clauss, Kevin
    Lee, Bradford W.
    Lee, Wendy W.
    Pasol, Joshua
    Ugradar, Shoaib
    Shinder, Roman
    Cockerham, Kimberly
    Wester, Sara
    Douglas, Raymond
    Kossler, Andrea Lora
    OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2025, 41 (01): : 111 - 112
  • [43] Hearing Dysfunction After Treatment With Teprotumumab for Thyroid Eye Disease
    Sears, Connie M.
    Azad, Amee D.
    Amarikwa, Linus
    Pham, Brandon H.
    Men, Clara J.
    Kaplan, Daniel N.
    Liu, Jocelyn
    Hoffman, Andrew R.
    Swanson, Austin
    Alyono, Jennifer
    Lee, Jennifer Y.
    Dosiou, Chrysoula
    Kossler, Andrea L.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2022, 240 : 1 - 13
  • [44] The Effect of Teprotumumab on Eyelid Position in Patients with Thyroid Eye Disease
    Simmons, Brittany A.
    Tran, Charlene
    Pham, Chau M.
    Shriver, Erin M.
    PLASTIC AND RECONSTRUCTIVE SURGERY-GLOBAL OPEN, 2022, 10 (04) : E4287
  • [45] The role of teprotumumab in chronic, clinically active thyroid eye disease
    Caroline Y. Yu
    Brittany A. Simmons
    Chau M. Pham
    Erin M. Shriver
    Eye, 2022, 36 : 1500 - 1501
  • [46] Teprotumumab improves light sensitivity in patients with thyroid eye disease
    Parunakian, Emanuil
    Ugradar, Shoaib
    Tolentino, Joseph
    Malkhasyan, Emil
    Raika, Pershanjit
    Ghaly, Joseph
    Bisht, Chirag
    Douglas, Raymond S.
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2024, 262 (09) : 2999 - 3006
  • [47] Teprotumumab for thyroid eye disease: early response is not required for benefit
    Ugradar, Shoaib
    Wang, Yao
    Mester, Tunde
    Kahaly, George J.
    Douglas, Raymond S.
    EYE, 2022, 36 (07) : 1403 - 1408
  • [48] Otologic Symptoms Following Teprotumumab Administration in Patients with Thyroid Eye Disease
    Epperson, Madison V.
    Hughes, Sara
    Valenzuela, Carla V.
    Stucken, Emily Z.
    OTOLOGY & NEUROTOLOGY, 2025, 46 (03) : 330 - 335
  • [49] Objective Diplopia Outcomes for Patients Treated With Teprotumumab for Thyroid Eye Disease
    Mudalegundi, Shwetha
    Huang, Peng
    Henderson, Amanda D.
    Carey, Andrew R.
    JOURNAL OF NEURO-OPHTHALMOLOGY, 2024, 44 (01) : 80 - 86
  • [50] Google Searches for Thyroid Eye Disease After Regulatory Approval of Teprotumumab
    Strawbridge, Jason C.
    Meer, Elana A.
    Singh, Pallavi
    Rootman, Daniel B.
    JAMA OPHTHALMOLOGY, 2022, 140 (06) : 639 - 642
12345